Mauled by a major setback, Incyte is pointing to a better future — but concedes it also had to scrap another failed study
At least Incyte $INCY has Jakafi.
With the biotech’s IDO1 pipeline effort foundering on bad data, Incyte today led off the annual update on its R&D effort with some good news. Jakafi, its primary cash contributor, met the primary endpoint in a pivotal study for steroid-refractory acute graft-versus-host disease, setting up a near-term supplemental drug application.
But while execs also spotlighted progress among its top-tier development efforts, Incyte also noted that it’s scrapping a clinical trial for INCB50465, a PI3Kδ drug, after it failed to measure up in patients with diffuse large B cell lymphoma. Three other trials for this drug are continuing, with the first cut on results expected in 2019.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
